Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $18.07 USD
Change Today +0.17 / 0.95%
Volume 128.2K
LMNX On Other Exchanges
As of 12:53 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMNX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/10/14 - $21.69
52 Week Low
02/3/15 - $15.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LUMINEX CORP (LMNX)

Related News

No related news articles were found.

luminex corp (LMNX) Related Businessweek News

No Related Businessweek News Found

luminex corp (LMNX) Details

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics and life sciences industries worldwide. It offers xMAP technology, an open architecture, multiplexing technology that allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The company’s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; respiratory viral family of products, including respiratory viral panel to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel family of products, such as in vitro diagnostic (IVD) assays to identify the pathogens causing infectious gastroenteritis. In addition, the company offers MultiCode assays and products comprising HSV1/2 kits, analyte specific reagents, and other products to detect infectious agents in clinical samples; cystic fibrosis family of products comprising IVD kits for cystic fibrosis genotyping; personalized medicine family of products consisting of assays to determine the drug metabolism status; and specialty product family and instrumentation products, as well as operates an original equipment manufacturer of custom reagents and instrumentation. It serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.

745 Employees
Last Reported Date: 02/25/15
Founded in 1995

luminex corp (LMNX) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $275.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $370.8K
Senior Vice President - Research & Developmen...
Total Annual Compensation: $327.0K
Chief Marketing & Sales Officer and Senior Vi...
Total Annual Compensation: $334.3K
Compensation as of Fiscal Year 2014.

luminex corp (LMNX) Key Developments

Luminex Corporation Receives FDA Clearance for ARIES® System and ARIES® HSV 1&2 Assay

Luminex Corporation announced that it has received FDA clearance for the company's ARIES® System and ARIES® HSV 1&2 Assay. ARIES® is a sample to answer system designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory environment. ARIES® uses internal barcode scanning and other advanced features to minimize operator errors. Two independent modules each support from one to six cassettes, allowing for both STAT and Batch testing IVD and MultiCode® Analyte Specific Reagents can be run simultaneously with a common Universal Assay Protocol. An integrated touchscreen PC eliminates the need for a separate computer, stand-alone keyboard, and mouse; thus maximizing valuable bench space. The company anticipates market launch in the next few weeks and a formal introduction at the Association for Molecular Pathology annual meeting in Austin, Texas, November 4-7, 2015.

Luminex Corporation - Special Call

To discuss the FDA clearance of the ARIES System and the ARIES HSV 1&2 Assay

Luminex Corporation Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-18-2015 11:40 AM

Luminex Corporation Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-18-2015 11:40 AM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Nachum Shamir, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNX:US $18.07 USD +0.17

LMNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $8.77 USD +0.02
HealthStream Inc $22.96 USD +0.24
Merge Healthcare Inc $7.13 USD +0.005
Meridian Bioscience Inc $17.64 USD +0.15
Quidel Corp $18.30 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation LMNX Industry Range
Price/Earnings 18.6x
Price/Sales 3.1x
Price/Book 2.1x
Price/Cash Flow 17.3x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at